Electrochemical sensing of dobutamine, paracetamol, amlodipine, and daclatasvir in serum based on thiourea SAMs over nano-gold particles–CNTs composite

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

TU-SAMs form in one-step over Au _nano/CNTs to determine four drugs simultaneously.

Abstract

We report in this work a one-step approach for the formation of self-assembled monolayers (SAMs) from thiourea (TU) over gold nanoparticles dispersed in carbon nanotubes (CNTs–Au _nano). The fabrication of the sensor is accomplished by drop-casting a thin film from an optimized mixture of CNTs, Au _nano, and TU over a GC electrode surface. The TU-SAMs electrochemical sensor is used for the simultaneous determination of dobutamine (DB), paracetamol (PA), amlodipine (AM), and daclatasvir (DAC), in human serum and in commercially available tablets. The proposed sensor is efficient, simple, and time saving in its preparation compared to other methods cited in the literature that need a longer time. The TU-SAMs sensor shows a high electrocatalytic effect for the simultaneous determination of DB, PA, AM, and DAC in human blood serum in concentration ranges 0.03 to 20 μM, 0.05 to 40 μM, 0.01 to 35 μM and 0.01 to 20 μM with low limits of detection of 0.85, 3.78, 0.65 and 0.60 nM respectively. The sensor shows good recoveries and resistance toward common interferents in human serum. The figures of merit such as stability, repeatability and robustness are presented.

Related collections

Most cited references 74

Record: found
Abstract: not found
Article: not found

Rational Design and General Synthesis of Multimetallic Metal–Organic Framework Nano‐Octahedra for Enhanced Li–S Battery

Wenting Li, Xiaotian Guo, Pengbiao Geng … (2021)

0 comments Cited 106 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

J Guedj, H Dahari, L Rong … (2013)

The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV). Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration. However, NS5A has no known enzymatic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to estimate its antiviral effectiveness. Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents. Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection experiments. The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, respectively, and yields a more precise estimate of the serum HCV half-life, 45 min, i.e., around four times shorter than previous estimates. Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline. However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion. The multiscale modeling approach, validated with in vitro kinetic experiments, brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.